Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of “Hold” by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $62.1667.

SUPN has been the subject of a number of research reports. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research report on Wednesday. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 20,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. The trade was a 56.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bethany Sensenig sold 4,475 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,185 shares of company stock valued at $1,268,022. Insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Hantz Financial Services Inc. raised its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $49,000. USA Financial Formulas purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth $50,000. EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $51,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $54.73 on Monday. The company’s 50-day simple moving average is $50.69 and its two-hundred day simple moving average is $48.39. The stock has a market capitalization of $3.14 billion, a P/E ratio of -80.48, a P/E/G ratio of 1.70 and a beta of 0.71. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.